RIVANNA Builds Momentum With AI-Guided Ultrasound Platforms and Expanding Clinical Evidence

RIVANNA advanced both its anesthesia and emergency imaging franchises this week, spotlighting the AI-guided Accuro 3S platform at the SOAP 2026 conference in Montreal while expanding clinical evidence around its Accuro XV system. The private medtech company is emphasizing AI-enabled guidance, workflow optimization, and structured early-access programs to build real-world data and support adoption.

At SOAP 2026, RIVANNA showcased Accuro 3S, an FDA-cleared platform designed to assist neuraxial anesthesia with automated landmark detection, continuous needle tip tracking, and a dual-array probe to improve midline access. The company’s Pioneer Partner program is now fully subscribed, and a new Trailblazer early-access cohort of 25 sites is being opened to generate outcome data and inform scalable deployment.

In emergency imaging, multiple peer-reviewed publications in the Journal of Emergency Medicine reported that non-physicians can acquire diagnostic-quality wrist and ankle scans using Accuro XV after just one hour of training. In a 205-patient study, image quality scores from clinical research assistants were statistically indistinguishable from those of board-certified emergency physicians, with more than 90% of scans deemed adequate for diagnosis.

The findings suggest Accuro XV’s automated volumetric acquisition and guided scanning path can materially reduce the ultrasound learning curve and support task-shifting of musculoskeletal imaging to trained support staff. Patient comfort was comparable to standard X-ray, reinforcing the platform’s potential as a radiation-free, point-of-triage solution in high-volume emergency settings.

RIVANNA also reported rapid expansion of its Accuro XV clinical program from two to eight U.S. academic sites, including UCSF, Yale, and UT Southwestern, with 10 systems deployed and 666 patients enrolled to date. The multicenter study, backed by BARDA funding, is building a large 3D imaging database to train the CADe/x automated fracture-detection algorithm and validate the BoneEnhance bone-visualization module for a planned FDA 510(k) submission.

Collectively, these developments underline RIVANNA’s strategy to pair proprietary hardware with AI-driven acquisition and interpretation, targeting recurring software and data revenue in emergency and neuraxial anesthesia markets. The growing clinical evidence base, government support, and structured early-access programs point to building momentum, though ultimate impact will depend on regulatory outcomes, reimbursement, and the pace of clinical adoption.